UniProt Q12866
Tyrosine-protein kinase Mer (Q12866)
Tyrosine-protein kinase Mer (UniProt Q12866), EC 2.7.10.1: 58 experimental structures on GenesisL1, 30 ligands bound, 23 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q12866
- Protein
- Tyrosine-protein kinase Mer
- EC
- 2.7.10.1
- Experimental structures
- 58
- Predicted models
- 0
- Ligands
- 30
- Pockets
- 23 · 11 records with a druggable one
Structures
58 records of Q12866 in the MolNFT archive: 58 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2DBJ | Solution structures of the fn3 domain of human Proto-oncogene tyrosine-protein kinase MER precursor | solution nmr | A | — | — |
| 2DBJ | Solution structures of the FN3 domain of human proto-oncogene tyrosine-protein kinase mer precursor | solution nmr | A | — | — |
| 2P0C | Catalytic Domain of the Proto-oncogene Tyrosine-protein Kinase MER | x-ray diffraction | A, B | — | — |
| 2P0C | Catalytic domain of the proto-oncogene tyrosine-protein kinase mer | x-ray diffraction | A, B | — | — |
| 3BPR | Crystal structure of catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex… | x-ray diffraction | A, B, C, D | — | — |
| 3BPR | Crystal structure of catalytic domain of the proto-oncogene tyrosine- protein kinase mer in complex… | x-ray diffraction | A, B, C, D | — | — |
| 3BRB | Crystal structure of catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex… | x-ray diffraction | A, B | — | — |
| 3BRB | Crystal structure of catalytic domain of the proto-oncogene tyrosine- protein kinase mer in complex… | x-ray diffraction | A, B | — | — |
| 3TCP | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in… | x-ray diffraction | A, B | — | — |
| 3TCP | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, B | — | — |
| 4M3Q | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in… | x-ray diffraction | A, B | — | — |
| 4M3Q | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, B | — | — |
| 4MH7 | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in… | x-ray diffraction | A, B | — | — |
| 4MH7 | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, B | — | — |
| 4MHA | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in… | x-ray diffraction | A, B | — | — |
| 4MHA | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, B | — | — |
| 5K0K | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in… | x-ray diffraction | A, B | CL, 6Q1, MG | 2 (best 0.74) |
| 5K0K | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, B | — | — |
| 5K0X | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, B | CL, K0X | — |
| 5TC0 | Structure-based optimization of 1H-imidazole-2-carboxamides as axl kinase inhibitors utilizing a… | x-ray diffraction | A, B | 79Y | — |
| 5TD2 | Structure-based optimization of 1H-imidazole-2-carboxamides as axl kinase inhibitors utilizing a… | x-ray diffraction | A, B | 7AE | — |
| 5U6C | Crystal structure of the mer kinase domain in complex with a macrocyclic inhibitor | x-ray diffraction | A, B | 7YS | — |
| 6MEP | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in… | x-ray diffraction | A, B | CL, 9VS, MG | — |
| 6MEP | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, B | CL, 9VS, MG | — |
| 7AAX | Crystal structure of MerTK kinase domain in complex with LDC1267 | x-ray diffraction | A | R6H, CL | 1 (best 0.71) |
| 7AAX | Crystal structure of mertk kinase domain in complex with LDC1267 | x-ray diffraction | A | R6H, CL | — |
| 7AAY | Crystal structure of MerTK kinase domain in complex with Merestinib | x-ray diffraction | A | L1X, CL | 1 (best 0.68) |
| 7AAY | Crystal structure of mertk kinase domain in complex with merestinib | x-ray diffraction | A | L1X, CL | — |
| 7AAZ | Crystal structure of mertk in complex with a type 1.5 aminopyridine inhibitor | x-ray diffraction | A | R6K, CL | — |
| 7AB0 | Apo crystal structure of the MerTK kinase domain | x-ray diffraction | A | CL | 2 (best 0.49) |
| 7AB0 | Apo crystal structure of the mertk kinase domain | x-ray diffraction | A | CL | — |
| 7AB1 | Crystal structure of mertk kinase domain in complex with gilteritinib | x-ray diffraction | A | C6F, CL | — |
| 7AB2 | Crystal structure of MerTK kinase domain in complex with UNC2025 | x-ray diffraction | A | R6N, CL | 2 (best 0.58) |
| 7AB2 | Crystal structure of mertk kinase domain in complex with UNC2025 | x-ray diffraction | A | R6N, CL | — |
| 7AVX | MerTK kinase domain in complex with NPS-1034 | x-ray diffraction | A, B | S4K | 3 (best 0.75) |
| 7AVX | Mertk kinase domain in complex with nps-1034 | x-ray diffraction | A, B | S4K | — |
| 7AVY | MerTK kinase domain in complex with quinazoline-based inhbitor | x-ray diffraction | A | S4E, SO4 | 3 (best 0.65) |
| 7AVY | Mertk kinase domain in complex with quinazoline-based inhbitor | x-ray diffraction | A | S4E, SO4 | — |
| 7AVZ | Mertk kinase domain in complex with a bisaminopyrimidine inhibitor | x-ray diffraction | A | S4N | — |
| 7AW0 | Mertk kinase domain in complex with purine inhibitor | x-ray diffraction | A | S4Q | — |
| 7AW1 | MerTK kinase domain in complex with a type 2 inhibitor | x-ray diffraction | A | S4T | 1 (best 0.71) |
| 7AW1 | Mertk kinase domain in complex with a type 2 inhibitor | x-ray diffraction | A | S4T | — |
| 7AW2 | Mertk kinase domain with type 1.5 inhibitor from a DNA-encoded library | x-ray diffraction | A | S4W | — |
| 7AW3 | Mertk kinase domain with type 1 inhibitor from a DNA-encoded library | x-ray diffraction | A | S4Z | — |
| 7AW4 | MerTK kinase domain with type 3 inhibitor from a DNA-encoded library | x-ray diffraction | A, B | S5E, CL | 4 (best 0.70) |
| 7AW4 | Mertk kinase domain with type 3 inhibitor from a DNA-encoded library | x-ray diffraction | A, B | S5E, CL | — |
| 7CQE | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in… | x-ray diffraction | A, C | CL, YDJ | — |
| 7CQE | Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in… | x-ray diffraction | A, C | CL, YDJ | — |
| 7DXL | Fragment-based lead discovery of indazole-based compounds as axl kinase inhibitors | x-ray diffraction | A, B | E56 | — |
| 7M5Z | Crystal structure of the mertk kinase domain in complex with inhibitor MIPS15692 | x-ray diffraction | A, B | YR7 | — |
| 7OAM | Kinase domain of mertk in complex with compound 8 | x-ray diffraction | A, B | V6H | — |
| 7OLS | MerTK kinase domain with type 1.5 inhibitor containing a di-methyl pyrazole group | x-ray diffraction | A | VJZ, CL | 2 (best 0.65) |
| 7OLS | Mertk kinase domain with type 1.5 inhibitor containing a di-methyl pyrazole group | x-ray diffraction | A | VJZ, CL | — |
| 7OLV | MerTK kinase domain with type 1.5 inhibitor containing a di-methyl, cyano pyrazole group | x-ray diffraction | A | VK2, CL | 1 (best 0.64) |
| 7OLV | Mertk kinase domain with type 1.5 inhibitor containing a di-methyl, cyano pyrazole group | x-ray diffraction | A | VK2, CL | — |
| 7OLX | Mertk kinase domain with type 1.5 inhibitor containing a tri-methyl pyrazole group | x-ray diffraction | A | VK5, CL | — |
| 9BHJ | MerTK in complex with small molecule 6-{1-[([1,1'-biphenyl]-4-yl)carbamoyl]azetidin-3-yl}-3-[(1-meth… | x-ray diffraction | A | A1APG, CL | 1 (best 0.72) |
| Q12866 | AlphaFold monomer V2.0 prediction for tyrosine-protein kinase mer (Q12866) | — | — | — |
Ligands
- CL · Chloride ion · in 24 records
- MG · Magnesium ion · in 3 records
- 9VS · cis-4-[(2-[(4-{[4-(1,3-dioxolan-2-yl)pyridin-2-yl]ethynyl}phenyl)amino]-5-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}pyrimidin-4-yl)amino]cyclohexan-1-ol · in 2 records
- L1X · N-(3-fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide · in 2 records
- R6H · ~{N}-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluoranyl-phenyl]-4-ethoxy-1-(4-fluoranyl-2-methyl-phenyl) pyrazole-3-carboxamide · in 2 records
- R6N · 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl) methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol · in 2 records
- S4E · N-(2-(2-cyclopropylethoxy)pyrimidin-5-yl)-7-methoxy-6-(piperidin-4-ylmethoxy)quinazolin-4-amine · in 2 records
- S4K · 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide · in 2 records
- S4T · N-(6-(4-(3-(4-((5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)methyl)-3-(trifluoromethyl)phenyl)ureido)phenoxy) pyrimidin-4-yl)cyclopropanecarboxamide · in 2 records
- S5E · 3-methyl-5-(4-methyl-1,2,3-thiadiazol-5-yl)-N-((R)-1-(((R)-3-(methylamino)-3-oxo-1-(4-(trifluoromethyl) phenyl)propyl)amino)-1-oxo-4-phenylbutan-2-yl) isoxazole-4-carboxamide · in 2 records
- SO4 · Sulfate ion · in 2 records
- VJZ · 5-[4-(1,5-dimethylpyrazol-4-yl)-2-methyl-phenyl]-~{N}-(imidazo[1,2-a]pyridin-6-ylmethyl)-~{N}-methyl-1,3,4-oxadiazol-2-amine · in 2 records
- VK2 · 4-[4-[5-[imidazo[1,2-a]pyridin-6-ylmethyl(methyl) amino]-1,3,4-oxadiazol-2-yl]-3-methyl-phenyl]-2,5-dimethyl-pyrazole-3-carbonitrile · in 2 records
- YDJ · 5-(3-fluorophenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide · in 2 records
- 6Q1 · 15-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-4,5,6,7,9,10,11,12-octahydro-2,16-(azenometheno)pyrrolo[2,1-d][1,3,5,9]te traazacyclotetradecin-8(3H)-one · in 1 record
- 79Y · N-(2-{4-[(2S)-4-(methylsulfonyl)morpholin-2-yl]-1,3-thiazol-2-yl}phenyl)-1H-imidazole-2-carboxamide · in 1 record
- 7AE · N-[2-{4-[(2S)-4-(methylsulfonyl)morpholin-2-yl]-1,3-thiazol-2-yl}-4-(morpholin-4-yl)phenyl]-1H-imidazole-2-carboxamide · in 1 record
- 7YS · (10R)-7-amino-11-chloro-12-fluoro-1-(2-hydroxyethyl)-3, 10,16-trimethyl-16,17-dihydro-1H-8,4-(azeno) pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one · in 1 record
- A1APG · 6-{1-[([1,1'-biphenyl]-4-yl)carbamoyl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide · in 1 record
- C6F · 6-ethyl-3-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]phenyl]amino]-5-(oxan-4-ylamino) pyrazine-2-carboxamide · in 1 record
- E56 · 3-[4-[6-chloranyl-5-[[(3R)-pyrrolidin-3-yl]amino]-1H-indazol-3-yl]pyrazol-1-yl]benzenecarbonitrile · in 1 record
- K0X · (7S)-7-amino-N-[(4-fluorophenyl)methyl]-8-oxo-2,9,16, 18,21-pentaazabicyclo[15.3.1]henicosa-1(21),17,19-triene-20-carboxamide · in 1 record
- R6K · 2-azanyl-~{N}-[(1~{S},2~{S})-2-[[4-[4-[(4-methylpiperazin-1-yl) methyl]phenyl]phenyl]methoxy]cyclopentyl]-5-(1-methylpyrazol-4-yl)pyridine-3-carboxamide · in 1 record
- S4N · (R)-N2-(4-(cyclopropylmethoxy)-3,5-difluorophenyl)-5-(3-methylpiperazin-1-yl)-N4-(tetrahydro-2H-pyran-4-yl)pyrimidine-2,4-diamine · in 1 record
- S4Q · 2-(cyclopentyloxy)-9-(2,6-difluorobenzyl)-N-methyl-9H-purin-6-amine · in 1 record
- S4W · 5-(2'-chloro-[1,1'-biphenyl]-4-yl)-N-(imidazo[1,2-a]pyridin-6-ylmethyl)-N-methyl-1,3,4-oxadiazol-2-amine · in 1 record
- S4Z · 2-(1-((5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxamido)methyl)-2-azabicyclo[2.1.1]hexan-2-yl)-N-methyl-4-(trifluoromethyl)thiazole-5-carboxamide · in 1 record
- V6H · 2-[[2,5-bis(fluoranyl)phenyl]methylamino]-4-(cyclopentylamino)-N-[3-(2-oxidanylidenepyrrolidin-1-yl)propyl]pyrimidine-5-carboxamide · in 1 record
- VK5 · ~{N}-[[3-[4-[(dimethylamino)methyl]phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]-~{N}-methyl-5-[3-methyl-5-(1,3, 5-trimethylpyrazol-4-yl)pyridin-2-yl]-1,3,4-oxadiazol-2-amine · in 1 record
- YR7 · 2-(butylamino)-N-[1-(3-fluoropropyl)piperidin-4-yl]-4-{[(1R,4R)-4-hydroxycyclohexyl]amino}pyrimidine-5-carboxamide · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.